Additionally, YAP can cooperate with ATF4 to drive sorafenib resistance in HCC [44–47], thus leading to the combination of the YAP inhibitor CA3 with sorafenib to treat HCC cells. This evidence concerns the gene YAP1 and hepatocellular carcinoma.